Vivek Ramaswamy is an American billionaire ... he initially worked in hedge fund investments before founding Roivant Sciences in 2014, focusing on pharmaceuticals. In 2023, he launched his ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Ramaswamy commented: "On behalf of the entire Roivant family, we are proud of this critical milestone for a promising therapy. This is an important moment for our team, and most significantly for ...

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

As of December 31, 2024, the Company had consolidated cash, cash equivalents, restricted cash, and marketable securities of approximately ...

Roivant Sciences has a twelve month low of $9.76 and a twelve month high of $13.06. Several research firms have recently weighed in on ROIV. HC Wainwright reissued a “buy” rating and issued a ...

Based on the one-year price targets offered by 7 analysts, the average target price for Roivant Sciences Ltd (NASDAQ:ROIV) is $17.14 with a high estimate of $22.00 and a low estimate of $13.00.

Roivant Sciences stock opened at $10.97 on Thursday. The stock has a market cap of $7.99 billion, a PE ratio of 1.94 and a beta of 1.25. The stock has a 50-day moving average price of $11.58 and a ...

Mahery hails most recently from Roivant Sciences, where she’d served as chief commercial officer since the summer of 2022. Before that, she spent the better part of two decades at EMD Serono ...

It’s show-me time for batoclimab, the FcRn-targeting antibody treatment from Immunovant and Roivant Sciences. A consequential Phase 3 study readout is coming before the end of the first quarter.